Ferozsons Laboratories Limited | |||||
Condensed Interim Unconsolidated Statement of Financial Position | |||||
As at 31 March 2026 | |||||
Un-audited | Audited | Un-audited | Audited | ||
31 March | 30 June | 31 March | 30 June | ||
2026 | 2025 | 2026 | 2025 | ||
EQUITY AND LIABILITIES ------------------- Rupees ------------------- ASSETS ------------------- Rupees ------------------- | |||||
Share capital and reserves | Non current assets | ||||
Authorized share capital | Property, plant and equipment | 6,356,811,216 | 6,322,793,986 | ||
150,000,000 (2025: 150,000,000) ordinary | Intangible assets | 7,917,573 | 23,644,069 | ||
shares of Rs. 10 each | 1,500,000,000 1,500,000,000 | Long term investments - related parties | 460,907,644 | 428,536,102 | |
Issued, subscribed and paid up capital 434,690,520 434,690,520 Capital reserve 321,843 321,843
Revaluation surplus on property,
Long term advances and deposits 63,169,067 30,987,166
6,888,805,500 6,805,961,323
plant and equipment 2,915,203,762 3,043,578,504 Current assets
Accumulated profit 6,345,082,231 5,886,718,190
264,512,157 | 110,979,476 |
5,322,829,931 | 4,925,439,120 |
2,603,711,653 | 2,097,262,852 |
238,664,506 | 158,050,821 |
138,032,351 | 194,490,091 |
154,134,358 | 238,552,201 |
241,084,994 | 398,675,869 |
431,039,651 | 402,631,388 |
305,863,953 | 345,584,088 |
9,695,298,356 9,365,309,057 Stores, spare parts and loose tools Stock in trade
Non current liabilities Trade debts
Loans and advances
Long term loans - secured
Long term musharaka - secured
Deferred grant Deferred taxation
Current liabilities
Deposits and prepayments Other receivables Advance income tax - net Short term investments
100,481,249 | 113,085,333 |
126,041,872 | 167,505,671 |
23,455,271 | 33,181,577 |
873,866,870 | 978,568,188 |
1,123,845,262 1,292,340,769 Cash and bank balances
9,699,873,554 8,871,665,906
Current portion of:
Long term loans - secured
Long term musharaka - secured
Deferred grant
Trade and other payables Contract liabilities
Short term borrowings - secured
Unclaimed dividend Accrued mark-up
21,982,859 | 20,649,201 |
51,817,282 | 47,046,072 |
13,048,300 | 14,381,958 |
2,448,521,305 | 2,224,133,875 |
167,936,726 | 319,467,819 |
2,897,020,584 | 2,218,996,474 |
105,054,541 | 99,116,101 |
64,153,839 | 76,185,903 |
5,769,535,436 5,019,977,403
Contingencies and commitments
16,588,679,054 15,677,627,229 16,588,679,054 15,677,627,229
Chief Executive Officer Chief Financial Officer Director
Ferozsons Laboratories Limited |
Condensed Interim Unconsolidated Statement of Profit or Loss (Un-audited) |
For the nine months and quarter ended 31 March 2026 |
Nine months ended Quarter ended |
31 March | 31 March | 31 March | 31 March |
2026 | 2025 | 2026 | 2025 |
Revenue - net |
Cost of sales |
Gross profit |
11,948,720,427 | 10,811,374,339 | 3,659,686,679 | 3,778,689,174 |
(6,958,894,727) | (6,521,768,268) | (2,120,952,475) | (2,255,786,189) |
4,989,825,700 | 4,289,606,071 | 1,538,734,204 | 1,522,902,985 |
Administrative expenses |
Selling and distribution expenses |
Other expenses |
Other income |
Profit from operations |
(682,512,332) |
(3,195,468,547) |
(127,461,961) |
84,699,018 |
1,069,081,878 |
(625,622,740) |
(2,701,670,080) |
(95,894,498) |
128,437,367 |
994,856,120 |
(201,773,982) |
(1,020,200,727) |
(32,398,684) |
35,579,896 |
319,940,707 |
(201,701,510) |
(1,037,145,839) |
(31,356,932) |
52,783,663 |
305,482,367 |
Finance cost |
Profit before income tax, final tax and |
minimum tax |
Minimum tax differential |
Profit before income tax |
Income tax |
Profit after taxation |
(223,662,937) | (357,083,721) | (71,692,654) | (81,299,937) |
845,418,941 | 637,772,399 | 248,248,053 | 224,182,430 |
(14,349,064) | (8,069,302) | (3,902,618) | 5,362,168 |
831,069,877 | 629,703,097 | 244,345,435 | 229,544,598 |
(327,204,370) | (239,260,459) | (94,095,571) | (91,428,024) |
Earnings per share - basic and diluted 11.59 8.98 3.46 3.18
Chief Executive Officer |
Chief Financial Officer |
Director |
Ferozsons Laboratories Limited |
Condensed Interim Unconsolidated Statement of Comprehensive Income (Un-audited) |
For the nine months and quarter ended 31 March 2026 |
Nine months ended | Quarter ended | |||
31 March | 31 March | 31 March | 31 March | |
2026 | 2025 | 2026 | 2025 | |
--------------------------------------------- Rupees --------------------------------------------- | ||||
Profit after taxation 503,865,507 390,442,638 150,249,864 138,116,574
Total comprehensive income for the period 503,865,507 390,442,638 150,249,864 138,116,574Chief Executive Officer |
Chief Financial Officer |
Director |
Ferozsons Laboratories Limited |
Condensed Interim Unconsolidated Statement of Changes in Equity |
For the nine months ended 31 March 2026 |
Reserve
Revaluation Total Capital reserve surplus on property, plant and equipment Accumulated profit -------------------------------------------Rupees------------------------------------------Balance as at 01 July 2024 | 434,690,520 | 321,843 | 3,212,263,581 | 5,320,197,432 | 8,967,473,376 |
Total comprehensive income for the period | - | - | - | 390,442,638 | 390,442,638 |
Surplus transferred to accumulated profit | |||||
- on account of incremental depreciation charged during the period - net of tax | - | - | (123,904,141) | 123,904,141 | - |
Transactions with owners of the Company, recognized directly in Equity - Distributions | |||||
- final dividend for the year ended 30 June 2024 at Rs. 3 per share | - | - | - | (130,407,156) | (130,407,156) |
Balance as at 31 March 2025 - unaudited | 434,690,520 | 321,843 | 3,088,359,440 | 5,704,137,055 | 9,227,508,858 |
Balance as at 01 July 2025 - audited | 434,690,520 | 321,843 | 3,043,578,504 | 5,886,718,190 | 9,365,309,057 |
Total comprehensive income for the period | - | - | - | 503,865,507 | 503,865,507 |
Surplus transferred to accumulated profit | |||||
- on account of incremental depreciation charged during the period - net of tax | - | - | (123,904,141) | 123,904,141 | - |
- on account of disposal of property, plant and equipment - net of tax | - | - | (4,470,601) | 4,470,601 | - |
Transactions with owners of the Company, recognized directly in Equity - Distributions | |||||
- final dividend for the year ended 30 June 2025 at Rs. 4 per share | - | - | - | (173,876,208) | (173,876,208) |
Balance as at 31 March 2026 - unaudited | 434,690,520 321,843 | 2,915,203,762 | 6,345,082,231 | 9,695,298,356 | |
Chief Executive Officer |
Chief Financial Officer |
Ferozsons Laboratories Limited |
Condensed Interim Unconsolidated Statement of Cash Flows (Un-audited) |
For the nine months ended 31 March 2026 |
Nine months ended | |
31 March | 31 March |
2026 | 2025 |
--------------------- Rupees --------------------
Profit before taxation |
Adjustments for non - cash and other items |
Depreciation on property, plant and equipment |
Amortisation of intangible assets |
Expected credit loss allowance |
Reversal of net realizable value |
Gain on disposal of property, plant and equipment |
Finance costs |
Unrealized gain on re-measurement of short term investments to fair value |
Gain on sale of short term investments |
Dividend income |
Profit on bank deposits |
Share in profit of Farmacia |
Provision for Workers' Profit Participation Fund |
Provision for Central Research Fund |
Workers' Welfare Fund |
Minimum tax |
Cash generated from operations before working capital changes Effect on cash flow due to working capital changes
(Increase) / decrease in current assets |
Stores, spare parts and loose tools |
Stock in trade |
Trade debts - considered good |
Loans and advances - considered good |
Deposits and prepayments |
Other receivables |
(Decrease) / Increase in current liabilities |
Trade and other payables |
Contract liability |
Cash generated from operations |
Tax paid |
Workers' Profit Participation Fund paid |
Workers' Welfare Fund paid |
Central Research Fund paid |
Net cash generated from operating activities |
Cash flow from investing activities |
Fixed capital expenditure incurred |
Intangibles acquired |
Proceeds from sale of property, plant and equipment |
Dividend income received |
Profit on bank deposits received |
Short term investments - net |
Long term deposits |
Net cash used in investing activities |
Cash flow from financing activities
Long term loan repaid |
Long term loan received |
Long term musharaka received |
Long term musharaka paid |
Finance cost paid |
Dividend paid |
Net cash used in financing activities |
Net (decrease) / increase in cash and cash equivalents |
Cash and cash equivalents at the beginning of the period |
Cash and cash equivalents at the end of the period |
Cash and cash equivalents comprise of the following
Cash and bank balances |
Short term borrowings - secured |
Chief Executive Officer |
831,069,877 629,703,097
481,729,605 |
18,684,485 |
37,104,698 |
(11,776,402) |
(15,207,286) |
223,662,937 |
(28,384,876) |
- |
(32,882) |
(2,596,290) |
(32,371,542) |
49,926,895 |
9,240,129 |
23,615,199 |
14,349,064 |
767,943,734 |
1,599,013,611 |
463,975,360 |
12,668,674 |
21,061,750 |
(38,885,078) |
(19,404,466) |
357,083,721 |
(39,650,159) |
(29,022,760) |
(28,565) |
(2,890,903) |
(23,785,045) |
34,407,129 |
6,950,935 |
15,963,049 |
8,069,302 |
766,512,944 |
1,396,216,041 |
(153,532,681) |
(385,614,409) |
(539,862,419) |
(80,613,685) |
52,766,660 |
84,417,843 |
(1,022,438,691) |
(26,977,324) |
119,515,970 |
(547,478,325) |
(133,409,554) |
(759,991) |
45,185,971 |
(543,923,253) |
205,820,542 756,485,093 |
(151,531,093) (87,074,678) |
54,289,449 669,410,415 |
(543,288,250) |
(2,957,989) |
42,748,701 |
32,882 |
2,596,290 |
- |
(32,181,901) |
(533,050,267) |
(286,333,244) |
- |
23,497,472 |
28,565 |
2,890,903 |
40,489,743 |
(177,175) |
(219,603,736) |
(22,330,390) (19,840,092) |
- 32,374,000 |
- 90,002,620 |
(36,692,589) (33,373,763) |
(235,695,001) (518,111,227) |
(167,937,768) (127,798,418) |
(462,655,748) (576,746,880) |
(717,744,245) 343,495,669 |
(1,873,412,386) (2,138,759,967) |
(2,591,156,631) (1,795,264,298) |
630,864,369 |
(288,663,877) |
(54,146,207) |
- |
(10,092,515) |
277,961,770 |
1,521,703,203 |
(329,552,078) |
(35,251,527) |
(10,427,178) |
(6,626,135) |
1,139,846,285 |
254,370,728 |
(2,049,635,026) |
(1,795,264,298) |
305,863,953
(2,897,020,584)
(2,591,156,631)
Chief Financial Officer |
Director
Ferozsons Laboratories Limited Condensed Interim Consolidated Statement of Financial Position As at 31 March 2026 | |||||
Un-audited 31 March | Audited 30 June | Un-audited 31 March | Audited 30 June | ||
2026 | 2025 | 2026 | 2025 | ||
------------------- Rupees ------------------- ------------------- Rupees ------------------- | |||||
EQUITY AND LIABILITIES | ASSETS | ||||
Share capital and reserves | Non-current assets | ||||
Authorized share capital | Property, plant and equipment | 11,691,057,787 | 11,556,822,174 | ||
150,000,000 (2025: 150,000,000) ordinary | Intangible assets | 10,620,655 | 27,627,559 | ||
shares of Rs. 10 each | 1,500,000,000 1,500,000,000 | Investment property | 79,371,992 | 79,371,992 | |
Issued, subscribed and paid up capital 434,690,520 434,690,520 Capital reserve 321,843 321,843
Revaluation surplus on property,
Long term advances and deposits 140,181,605 42,835,216
11,921,232,039 11,706,656,941
plant and equipment - net of tax 3,387,688,806 3,543,841,204 Current assets
Accumulated profits 9,114,071,416 8,396,342,572
375,347,854 | 205,910,578 |
7,981,730,200 | 6,600,503,373 |
3,231,201,601 | 2,301,227,364 |
450,731,077 | 255,608,821 |
159,227,138 | 284,042,284 |
202,677,920 | 285,309,001 |
468,867,438 | 612,129,972 |
1,074,605,814 | 1,661,032,001 |
597,185,417 | 692,527,117 |
Equity attributable to owners of the Company 12,936,772,585 12,375,196,139 Stores, spare parts and loose tools Stock in trade
Non-controlling interests 2,275,723,723 2,091,492,320 Trade debts
15,212,496,308 14,466,688,459 Loans and advances Deposits and prepayments
Non current liabilities Other receivables
Advance income tax - net
Long term loans - secured
Long term musharaka - secured Deferred grant
Deferred taxation
1,220,019,761 | 1,418,820,425 |
175,354,121 | 229,111,824 |
262,907,637 | 351,552,962 |
1,485,447,057 | 1,486,659,972 |
3,143,728,576 3,486,145,183
Short term investments Cash and bank balances
14,541,574,459 12,898,290,511
Current liabilities
Current portion of:
Long term loans - secured
Long term musharaka - secured
Deferred grant
Trade and other payables Contract liabilities
Short term borrowings - secured Unclaimed dividend
Accrued mark-up
345,138,321 | 334,669,603 |
67,547,823 | 61,075,146 |
118,131,713 | 128,490,379 |
4,078,362,652 | 3,346,868,600 |
198,035,797 | 340,839,485 |
3,113,100,867 | 2,248,359,022 |
105,054,541 | 99,116,101 |
81,209,900 | 92,695,474 |
8,106,581,614 6,652,113,810
Contingencies and commitments
26,462,806,498 24,604,947,452 26,462,806,498 24,604,947,452
Chief Executive Officer Chief Financial Officer Director
Ferozsons Laboratories Limited |
Condensed Interim Consolidated Statement of Profit or Loss (Un-audited) |
For the nine months and quarter ended 31 March 2026 |
Nine months ended Quarter ended | |||
31 March | 31 March | 31 March | 31 March |
2026 | 2025 | 2026 | 2025 |
5,550,411,818 |
(3,038,019,525) |
2,512,392,293 |
Revenue - net |
Cost of sales |
Gross profit |
18,172,263,314 | 14,351,833,605 | 5,091,896,588 |
(10,000,011,709) | (8,337,868,798) | (3,020,649,913) |
8,172,251,605 | 6,013,964,807 | 2,071,246,675 |
Administrative expenses |
Selling and distribution expenses |
Other expenses |
Other income |
Profit from operations |
(846,601,788) | (691,423,837) | (274,522,512) |
(5,348,235,979) | (3,803,189,090) | (1,710,785,874) |
(243,382,844) | (154,589,020) | (55,271,848) |
149,920,160 | 198,924,556 | 47,653,474 |
1,883,951,154 | 1,563,687,416 | 519,465,533 |
(225,228,522) |
(1,361,659,412) |
(54,141,135) |
80,276,165 |
510,493,771 |
Finance cost |
Profit before income tax, final tax and |
minimum tax differential |
(23,894,949) | (9,390,332) | (3,700,481) |
1,563,727,287 | 1,079,182,766 | 422,508,938 |
(644,043,230) | (412,806,015) | (169,223,890) |
Minimum tax differential and final tax |
Profit before taxation |
Taxation |
Profit after taxation |
Attributable to:
919,684,057 666,376,751 253,285,0484,253,580 405,027,122
(157,221,480) |
247,805,642 |
Owners of the Group |
Non-controlling interests |
Profit after taxation |
735,452,654 | 570,316,302 207,765,612 |
184,231,403 | 96,060,449 45,519,436 |
919,684,057 | 666,376,751 253,285,048 |
199,466,655 |
48,338,987 |
247,805,642 |
Earnings per share - basic and diluted 16.92 13.12 4.78 4.59
Chief Executive Officer |
Chief Financial Officer |
Director |
Ferozsons Laboratories Limited |
Condensed Interim Consolidated Statement of Comprehensive Income (Un-audited) |
For the nine months and quarter ended 31 March 2026 |
Nine months ended | Quarter ended | ||
31 March | 31 March | 31 March | 31 March |
2026 | 2025 | 2026 | 2025 |
-------------------------------------------------- Rupees -------------------------------------------------- | |||
Total comprehensive income for the period 919,684,057 666,376,751 253,285,048 247,805,642
Attributable to:
Owners of the Group |
Non-controlling interests |
735,452,654 | 570,316,302 207,765,612 |
184,231,403 | 96,060,449 45,519,436 |
919,684,057 | 666,376,751 253,285,048 |
199,466,655
48,338,987
247,805,642
Chief Executive Officer |
Chief Financial Officer |
Director |
Ferozsons Laboratories Limited |
Condensed Interim Consolidated Statement of Changes in Equity |
For the nine months ended 31 March 2026 |
Attributable to Owners of the Company | |||
Capital reserve | Revenue reserve | ||
Share capital | Capital reserve | Revaluation surplus on property, plant and equipment | Total Non-controlling Total Accumulated interest profits |
Transactions with owners of the Company, recognized directly in Equity - Distributions |
- final dividend for the year ended 30 June 2024 at Rs. 3 per share |
- issuance of new shares by subsidiary to NCI net of transaction cost |
- effect of change in ownership without loss of control |
- |
- |
- |
- |
- |
- |
- |
- |
- |
(130,407,156) |
- |
501,315,741 |
- |
1,855,198,135 |
(501,315,741) |
(130,407,156) |
1,855,198,135 |
- |
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Rupees - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Balance as at 01 July 2024 - audited | 434,690,520 | 321,843 | 3,753,246,119 | 7,040,048,601 | 11,228,307,083 | 591,877,248 | 11,820,184,331 |
Total comprehensive income for the period | - | - | - | 570,316,302 | 570,316,302 | 96,060,449 | 666,376,751 |
Surplus transferred to accumulated profit: - on account of incremental depreciation charged during the period - net of tax | - | - | (155,459,441) | 155,459,441 | - | - | - |
(130,407,156) | |||||||
501,315,741 | |||||||
Balance as at 31 March 2025 - un-audited | 434,690,520 | 321,843 | 3,597,786,678 | 8,136,732,929 | 12,169,531,970 | 2,041,820,091 | 14,211,352,061 |
Balance as at 01 July 2025 - audited | 434,690,520 | 321,843 | 3,543,841,204 | 8,396,342,572 | 12,375,196,139 | 2,091,492,320 | 14,466,688,459 |
Total comprehensive income for the period | - | - | - | 735,452,654 | 735,452,654 | 184,231,403 | 919,684,057 |
Surplus transferred to accumulated profit: | |
- | on account of incremental depreciation charged during the period - net of tax |
- | on account of disposal of property, plant and equipment - net of tax |
- |
- |
- |
- |
(151,681,797) |
(4,470,601) |
151,681,797 |
4,470,601 |
- |
- |
- |
- |
- |
- |
Transactions with owners of the Company, recognized directly in equity - distributions | |||||||
- final dividend for the year ended 30 June 2025 at Rs. 4 per share | - | - | - | (173,876,208) | (173,876,208) | - | (173,876,208) |
Balance as at 31 March 2026 - un-audited | 434,690,520 | 321,843 | 3,387,688,806 | 9,114,071,416 | 12,936,772,585 | 2,275,723,723 | 15,212,496,308 |
Chief Executive Officer |
Chief Financial Officer |
Director |
Ferozsons Laboratories Limited |
Condensed Interim Consolidated Statement of Cash Flows (Un-audited) |
For the nine months ended 31 March 2026 |
Nine months ended | |
31 March | 31 March |
2026 | 2025 |
---------------------- Rupees --------------------- | |
Cash flow from operating activities
Profit before taxation |
Adjustments for non - cash and other items |
Depreciation on property, plant and equipment |
Amortization of intangible assets |
Expected credit loss allowance |
Net realizable value adjustment for the period |
Gain on disposal of property, plant and equipment |
Finance costs |
Unrealized gain on re-measurement of short term investments to fair value |
Gain on sale of short term investments |
Dividend income |
Minimum tax differential |
Profit on deposits with bank |
Workers' Profit Participation Fund |
Central Research Fund |
Workers' Welfare Fund |
Cash generated from operations before working capital changes
Effect on cash flow due to working capital changes |
(Increase) / decrease in current assets |
Stores, spare parts and loose tools |
Stock in trade |
Trade debts |
Loans and advances - considered good |
Deposits and prepayments |
Other receivables |
Increase / (decrease) in current liabilities |
Trade and other payables |
Contract liabilities |
Cash generated from operations |
Tax paid |
Workers' Profit Participation Fund paid |
Workers' Welfare Fund paid |
Central Research Fund paid |
Net cash generated from operating activities |
Cash flow from investing activities |
Purchase of property, plant and equipment |
Acquisition of intangibles |
Dividend income received |
Proceeds from sale of property, plant and equipment |
Long term advances and deposits |
Profit on bank deposits received |
Short term investments - net |
Net cash used in investing activities |
Cash flow from financing activities |
Proceeds from Initial Public Offering - net |
Long term musharaka received |
Long term musharaka paid |
Long term loan received |
Long term loan paid |
Finance cost paid |
Dividend paid |
Net cash (used in) / generated from financing activities |
Net (decrease) / increase in cash and cash equivalents |
Cash and cash equivalents at the beginning of the period |
Cash and cash equivalents at the end of the period |
Cash and cash equivalents comprise of the following: |
Cash and bank balances |
Short term borrowings - secured |
Chief Executive Officer |
1,563,727,287 1,079,182,766
761,321,582 |
19,964,893 |
70,620,955 |
11,125,917 |
(18,144,561) |
292,140,662 |
(68,064,730) |
(16,760,172) |
(32,882) |
23,894,949 |
(9,223,173) |
93,973,257 |
18,138,384 |
40,352,817 |
1,219,307,898 |
2,783,035,185 |
666,488,062 |
13,795,096 |
27,311,572 |
39,583,870 |
(20,772,370) |
472,985,601 |
(90,992,808) |
(56,239,428) |
(28,565) |
9,390,332 |
(22,173,374) |
64,648,404 |
12,630,240 |
26,645,821 |
1,143,272,453 |
2,222,455,219 |
(169,437,276) |
(1,392,352,744) |
(1,000,595,192) |
(195,122,256) |
124,815,146 |
82,631,081 |
(2,550,061,241) |
(109,946,110) |
(826,559,318) |
(726,203,666) |
(248,650,994) |
84,848,410 |
48,667,551 |
(1,777,844,127) |
681,756,614 | 1,305,876,700 |
(142,803,688) | (83,552,845) |
771,926,870 | 1,666,934,947 |
(525,888,560) | (543,111,538) |
(84,782,207) | (68,013,750) |
- | (18,085,235) |
(17,944,812) | (12,940,472) |
143,311,291 | 1,024,783,952 |
(926,565,872) |
(2,957,989) |
32,882 |
49,153,237 |
(97,346,389) |
9,223,173 |
671,251,089 |
(297,209,869) |
(491,940,120) |
(5,121,630) |
28,565 |
25,509,423 |
(187,175) |
22,173,374 |
(903,181,289) |
(1,352,718,852) |
- 1,855,198,135 |
- 183,554,428 |
(47,285,026) (48,059,810) |
- 32,374,000 |
(304,751,984) (250,559,528) |
(286,210,189) (609,586,506) |
(167,937,768) (127,798,418) |
(806,184,967) 1,035,122,301 |
(960,083,545) 707,187,401 |
(1,555,831,905) (2,191,969,793) |
(2,515,915,450) (1,484,782,392) |
567,076,274 |
(2,051,858,666) |
(1,484,782,392) |
597,185,417
(3,113,100,867)
(2,515,915,450)
Chief Financial Officer |
Director